Measuring and Enhancing Creativity and Brain Flexibility in Adolescents With Depression
18. mai 2026 oppdatert av: University of Minnesota
This research is designed to find out if engaging in creative activities will help adolescents with depression have more flexible thinking, start to see and appreciate their own talents, and develop a more positive view of themselves and their future.
Studieoversikt
Studietype
Intervensjonell
Registrering (Faktiske)
160
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55455
- University of Minnesota
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
Tar imot friske frivillige
Ja
Beskrivelse
Inclusion Criteria:
- age 12-17 years
- Phase 1: no clinical diagnosis required.
- Phase 2: presence of at least "mild" depression symptoms as measured by a score of at least 12 on the parent-report Children's Depression Inventory (CDI) (completed in the screening form).
- Phase 2, Summer 2025 East African cohort: The adolescent identifies as East African.
- Phase 2, Summer 2025 Native American cohort: The adolescent identifies as Native American.
Exclusion Criteria:
- any MRI contraindications (e.g., claustrophobia, braces, pregnancy); Note: MRI exclusion is removed for Summer 2023 and 2025 cohorts since the neuroimaging has been removed from the protocol for those cohorts
- neurodevelopmental disorder such as intellectual disability or moderate / severe autism, as indicated by parent report;
- significant medical conditions that would interfere with participating in study activities;
- currently active suicidal ideation, and unable to agree to an appropriate safety plan
- history of significant neurological conditions that might confound MRI analyses (e.g., current and severe epilepsy, brain tumor). Note: this exclusion is removed for Summer 2023 and 2025 cohorts since they will not have MRI.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Creativity Camp
All participants who enrolled in the study were assigned to the Creativity Camp. In Summer 2022, participants were 1:1 randomized to "early" (2 weeks before camp, before camp, after camp) or "late" assessments (before camp, after camp, and 2 weeks after camp). This allowed for an approximation of a waitlist-control design, where we compared the changes during the "waitlist" (the two weeks before camp for the "early" group) to the changes during camp for the "active" group (changes from pre to post intervention for the "late" group) and also allowed us to explore short-term durability of effects in the "late" group. In 2023 and 2025, since MRI was no longer required, clinical data were collected at all 4 time points: 2 weeks before, before camp, after camp, and 2 weeks after camp. This allows for analysis of the data using a "waitlist control" approach while not changing the experience at the level of the participant. |
An 8-day creativity camp that includes a variety of different kinds of creative arts activities.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Child Depression Inventory 2 (CDI-2).
Tidsramme: Week 2
|
The CDI (2) is a self-report questionnaire completed by child and parent separately.
The Child CDI 2 is a 28-item measure of depression symptoms for youth ages 7-17.
For each item, participants selected one of three choices that describe the severity of their symptoms over the past 2 weeks.
Responses are: 0 (no symptoms), 1 (mild or probable symptoms), or 2 (definite symptoms).
The 17-item Parent CDI 2, has four choices per item, ranging from 0 (not at all) to 3 (much or most of the time).
For both child and parent reports, higher scores mean more severe depression.
|
Week 2
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The Screen for Child Anxiety Related Disorders (SCARED)
Tidsramme: Month 3
|
The SCARED is a 41-item inventory of anxiety symptoms rated on a 3-point Likert-type scale.
Higher scores mean higher severity of anxiety.
|
Month 3
|
|
The Zest for Life Scale (ZLS)
Tidsramme: Week 1
|
This 12-item questionnaire assesses engagement, enthusiasm, and positive outlook on life in the last week.
Each of the 12 items is rated on a 9-point Likert scale ranging from 0 (not at all) to 8 (very strongly).
The minimum possible score is 0, and the maximum is 96.
Higher scores on the scale indicate a greater zest for life.
|
Week 1
|
|
The Flourishing Scale
Tidsramme: Week 2
|
In this 8-item questionnaire, participants rate on a 1-7 scale their agreement with statements regarding perceptions of their life's meaning and purpose, view of self and how they fit into the world.
Maximum score is 56.
Higher scores mean higher levels of well-being.
|
Week 2
|
|
The Satisfaction with Life Scale
Tidsramme: Week 2
|
The Satisfaction with Life Scale assesses overall life satisfaction, with 5 questions on a 1-7 scale.
Maximum score is 35.
Higher scores mean higher life satisfaction.
|
Week 2
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. juni 2022
Primær fullføring (Faktiske)
31. august 2025
Studiet fullført (Faktiske)
31. august 2025
Datoer for studieregistrering
Først innsendt
18. mai 2026
Først innsendt som oppfylte QC-kriteriene
18. mai 2026
Først lagt ut (Faktiske)
26. mai 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
26. mai 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
18. mai 2026
Sist bekreftet
1. mai 2026
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- PSYCH-2021-30129
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .